Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImVisioN Therapeutics, a biopharmaceutical company, has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for cat dander allergy.
Subscribe to our email newsletter
The primary objective of this first human clinical study on ImVisioN’s lead product IVN201 for the treatment of cat dander allergies will be product safety, but the study will also assess several efficacy parameters.
The first patient has been enrolled for this placebo controlled, double blind trial, conducted at the University Hospital in Zurich, Switzerland. The study will include a total of 20 patients allergic to cat dander and is expected to complete in the second quarter of 2009.
The company also announced the closing of a series A financing round of CHF4.6 million, allowing the clinical development of IVN201. The financing round was led by Aravis Venture Associates and involved the participation of the founding investor Nextech Venture and private individuals.
Martin Steiner, ImVisioN’s CEO and co-founder, said: “This financing allows ImVisioN to conduct the first human studies on IVN201 for the treatment of cat dander allergy.
“This intralymphatic immunotherapeutic allows for the treatment of this common allergy with a minimum of injections leading to faster and more effective desensitization. This is the first product in our pipeline, which also includes treatments for other frequent allergies such as those caused by birch pollen or house dust mites.”